Rchr
J-GLOBAL ID：202101015432063381
Update date: Feb. 01, 2024
Shimokawa Masahiro
シモカワ マサヒロ | Shimokawa Masahiro
Affiliation and department：
Research field (1)：
Digestive surgery
Research theme for competitive and other funds (2)：
- 2021 - 2024 Elucidation of molecular mechanism about anti-tumor immune evasion by beta-catenin in hepatocellular carcinoma and its therapeutic application
- 2016 - 2019 The roles of Nrf2 on progression in hepatocellular carcinoma
Papers (17)：
-
Takahiro Tomiyama, Masahiro Shimokawa, Noboru Harada, Katsuya Toshida, Akinari Morinaga, Yukiko Kosai-Fujimoto, Takahiro Tomino, Takeshi Kurihara, Yoshihiro Nagao, Takeo Toshima, et al. Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation. Hepatology research : the official journal of the Japan Society of Hepatology. 2022. 52. 10. 872-881
-
Norifumi Iseda, Shinji Itoh, Katsuya Toshida, Takahiro Tomiyama, Akinari Morinaga, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Takeo Toshima, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer science. 2022. 113. 7. 2272-2287
-
Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, et al. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatology communications. 2021. 6. 4. 665-678
-
Masafumi Akasu, Shu Shimada, Ayano Kabashima, Yoshimitsu Akiyama, Masahiro Shimokawa, Keiichi Akahoshi, Atsushi Kudo, Shoji Yamaoka, Minoru Tanabe, Shinji Tanaka. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Scientific reports. 2021. 11. 1. 16732-16732
-
Ayano Kabashima, Shu Shimada, Masahiro Shimokawa, Yoshimitsu Akiyama, Minoru Tanabe, Shinji Tanaka. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. Journal of hepato-biliary-pancreatic sciences. 2021. 28. 1. 62-75
ｍore...
MISC (71)：
-
谷合智彦, 谷合智彦, 下川雅弘, 田中真二. 予後不良型肝細胞癌の分子生物学的特徴と複合免疫療法が癌微小環境に及ぼす影響. 肝臓. 2022. 63. Supplement 1
-
谷合智彦, 谷合智彦, 島田周, 秋山好光, 新部綾乃, 下川雅弘, 田中真二. 同種移植モデルを用いたVETC/MTM形成肝細胞癌の分子生物学的特徴及び癌免疫微小環境に及ぼす影響. 日本肝がん分子標的治療研究会プログラム・抄録集. 2022. 26th
-
石井武, 秋山好光, 下川雅弘, 浅野大輔, 石川喜也, 上田浩樹, 赤星径一, 新部彩乃, 島田周, 小川康介, et al. 膵癌におけるヒストン修飾酵素SETD1Aの新規標的遺伝子の同定と臨床的意義の解明. 日本外科学会定期学術集会(Web). 2022. 122nd
-
田中 真二, 島田 周, 秋山 好光, 新部 彩乃, 波多野 恵, 下川 雅弘, 田邉 稔, 小川 佳宏. 肝臓の慢性炎症(ウィルス性と栄養性)と肝がんの発症 肝臓外科からみた代謝関連肝癌の分子機序と治療戦略. 糖尿病. 2021. 64. Suppl.1. LD-3
-
下川雅弘, 田中真二. Mesenchymal hamartoma of the liver. 日本臨床. 2021
ｍore...
Education (3)：
- 2014 - 2020 Kyushu University Graduate School of Medical Sciences Department of Surgery and Sciences
- 2006 - 2012 Kyushu University School of Medicine
- 2000 - 2004 The University of Tokyo
Work history (6)：
Return to Previous Page
